Free Trial
→ Don't lose access to this (From TradeWins) (Ad)tc pixel
NASDAQ:FTH

Sensei Biotherapeutics Q3 2026 Earnings Results & Report

Sensei Biotherapeutics logo
$19.80 +0.58 (+2.99%)
As of 11:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Sensei Biotherapeutics missed analyst earnings expectations in its Q3 2026 results, released November 3, 2026. The company reported EPS of -$0.79 versus the -$0.66 consensus estimate.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Sensei Biotherapeutics EPS Results

Actual EPS
-$0.79
Consensus EPS
-$0.66
Beat/Miss
Missed by -$0.13
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Sensei Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

Sensei Biotherapeutics' Q3 2026 Press ReleasePress Release
(8-K)
Sensei Biotherapeutics' Q3 2026 Quarterly reportQuarterly report
(10-Q)

Sensei Biotherapeutics Q3 2026 Earnings FAQ

Sensei Biotherapeutics (NASDAQ:FTH) reported earnings of -$0.79 per share for Q3 2026, missing the consensus estimate of -$0.66. The report was announced on Tuesday, November 3, 2026.

Sensei Biotherapeutics Earnings Headlines

Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates
 |  businesswire.comhttps://www.businesswire.com/news/home/20261103631868/en/Faeth-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Operational-Updates/
Sensei Biotherapeutics (NASDAQ:FTH) Earns "Buy" Rating from BTIG Research
October 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31164941
I'm handing you this one free
Elon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.tc pixel
November 3 at 1:00 AM  |  Behind the Markets (Ad)
Equities Analysts Offer Predictions for FTH FY2028 Earnings
October 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31164670
Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib
October 23, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261023657226/en/Faeth-Presents-Updated-Preclinical-Data-at-ESMO-including-First-Ever-Head-to-Head-Characterization-of-PIKTOR-against-Gedatolisib/
Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026
October 19, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261019736343/en/faeth-to-present-preclinical-data-on-piktor-in-hrher2--breast-cancer-models-at-esmo-2026/
See More Sensei Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sensei Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sensei Biotherapeutics and other key companies, straight to your email.

About Sensei Biotherapeutics

Sensei Biotherapeutics (NASDAQ:FTH) is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is designed to activate and direct the immune system against tumors, with an emphasis on treatments that may address immune-suppressive mechanisms in the tumor microenvironment.

Sensei’s pipeline has included SNS-101, an investigational antibody targeting VISTA, an immune checkpoint believed to limit anti-tumor immune responses, and SNS-301, an investigational cancer vaccine developed using the company’s ImmunoPhage platform. The platform is intended to combine tumor-associated antigens with immune-stimulating components to promote targeted cancer immune responses. The company has studied these candidates in early-stage clinical development, including potential use in combination with other cancer therapies.

Sensei Biotherapeutics is headquartered in the United States and has focused primarily on research and clinical development rather than commercialized products. The company’s shares have historically traded on Nasdaq under the symbol SNSE; the symbol FTH provided in the request does not appear to correspond to Sensei Biotherapeutics.

View Sensei Biotherapeutics Profile
Earnings Tools